A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients

Background Histones released in response to cellular injury are important mediators of organ failure and death in sepsis. Preclinical studies demonstrate that neutralization of histones in sepsis is associated with improved outcome. M6229 is a low-anticoagulant heparin able to neutralize histones. W...

Full description

Saved in:

Bibliographic Details
Published in:	Intensive care medicine experimental Vol. 13; no. 1; pp. 84 - 15
Main Authors:	van Mourik, Niels, van Amstel, Rombout B. E., Slim, Marleen A., van Vught, Lonneke A., van der Poll, Tom, Huckriede, Joram, de Vries, Femke, de Kimpe, Sjef J., Crabbé, Raf, van Leeuwen, Simone J. M., Ekhart, Peter F., Reutelingsperger, Chris P. M., Nicolaes, Gerry A. F., Vlaar, Alexander P. J., Müller, Marcella C. A.
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 18.08.2025 Springer Nature B.V SpringerOpen
Subjects:	Anticoagulants Coronaviruses COVID-19 Critical Care Medicine Histones Human subjects Illnesses Intensive M6229 Medical research Medicine Medicine & Public Health Mortality Neutralization Patients Pharmacodynamics Pharmacokinetics Phase I Plasma Sepsis Septic shock Netherlands Phase I M6229 Histones Sepsis Septic shock Heparin Safety Pharmacokinetics Neutralization
ISSN:	2197-425X, 2197-425X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!